https://orcid.org/0000-0001-5361-3001
Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Silvia Ricci, Chiara Azzari, Emanuele Amodio & Paolo Castiglia. (2023) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT): A review of the evidence and expert opinion. Expert Review of Vaccines 22:1, pages 447-456.
Read now
Read now
Corwin A. Robertson, Jeffry Jacqmein, Alexandre Selmani, Katherine Galarza & Philipp Oster. (2023) Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study. Human Vaccines & Immunotherapeutics 19:1.
Read now
Read now
Gary S. Marshall, Stephen I. Pelton, Corwin A. Robertson & Philipp Oster. (2022) Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Markus Knuf, Mika Rämet, Nina Breinholt Stærke, Isabelle Bertrand-Gerentes, Yaël Thollot, Siham B'Chir, Habiba Arroum & Philipp Oster. (2022) Comparing the meningococcal serogroup C immune response elicited by a tetanus toxoid conjugate quadrivalent meningococcal vaccine (MenACYW-TT) versus a quadrivalent or monovalent C tetanus toxoid conjugate meningococcal vaccine in healthy meningococcal vaccine-naïve toddlers: A randomised, controlled trial. Human Vaccines & Immunotherapeutics 18:5.
Read now
Read now
Franco M. Piazza, Miia Virta, Marita Paassilta, Benita Ukkonen, Anitta Ahonen, Alejandra Esteves-Jaramillo, Aino Forsten, Ilkka Seppa, Jian Ding, David Neveu, Emilia Jordanov & Mandeep S. Dhingra. (2022) Immunogenicity and safety of an investigational quadrivalent meningococcal conjugate vaccine administered as a booster dose in children vaccinated against meningococcal disease 3 years earlier as toddlers: A Phase III, open-label, multi-center study. Human Vaccines & Immunotherapeutics 18:1, pages 1-10.
Read now
Read now
Sarah Schaffer DeRoo, Rachel G. Torres & Linda Y. Fu. (2021) Meningococcal disease and vaccination in college students. Human Vaccines & Immunotherapeutics 17:11, pages 4675-4688.
Read now
Read now
Federico Martinón-Torres, Isabelle Bertrand-Gerentes & Philipp Oster. (2021) A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Review of Vaccines 20:9, pages 1123-1146.
Read now
Read now
Articles from other publishers (14)
David Neveu, Tamala Mallett Moore, Betzana Zambrano, Aiying Chen, Marie-Laure Kürzinger, Lydie Marcelon & Mandeep Singh Dhingra. (2023) Structured Benefit-Risk Assessment of a New Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) in Individuals Ages 12 Months and Older. Infectious Diseases and Therapy 12:10, pages 2367-2386.
Crossref
Crossref
Betzana Zambrano, James Peterson, Carmen Deseda, Katie Julien, Craig A. Spiegel, Clifford Seyler, Michael Simon, Robert Hoki, Marc Anderson, Brad Brabec, Germán Áñez, Jiayuan Shi, Judy Pan, Audrey Hagenbach, Dalia Von Barbier, Kucku Varghese, Emilia Jordanov & Mandeep Singh Dhingra. (2023) Quadrivalent meningococcal tetanus toxoid-conjugate booster vaccination in adolescents and adults: phase III randomized study. Pediatric Research 94:3, pages 1035-1043.
Crossref
Crossref
Osamu Matsuoka, Mugen Ujiie, Hitoshi Kikuchi, Sachiko Otake, Danaya Chansinghakul, Takahiro Inoue, Kucku Varghese, Nuchra Sirisuphmitr, Tomoyuki Hashiguchi, Betzana Zambrano, Takahiro Nakama, Carina Frago, Emilia Jordanov & Mandeep Singh Dhingra. (2023) Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) in Meningococcal Vaccine-Naïve Participants across a Broad Age Range (2–55 Years) in Japan: a Phase III Randomized Study. Japanese Journal of Infectious Diseases 76:3, pages 174-182.
Crossref
Crossref
L. S. Namazova-Baranova, O. A. Perminova, T. A. Romanova, V. V. Romanenko, A. N. Galustyan, V. N. Gorodin, I. V. OsipovaV. Yu. Rodnikova, S. M. Kharit, Yu. V. Kovshirina, V. А. Anokhin, S. B’Chir, D. Neveu, M. Bonaparte, G. Áñez, E. Jordanov, M. S. Dhingra & A. V. Goldstein. (2023) Immunogenicity and Safety of a Quadrivalent Meningococcal Tetanus Toxoid-Conjugate Vaccine (MenACYW-TT) Administered Concomitantly with Pneumococcal Conjugate Vaccine in Healthy Toddlers in the Russian Federation: a Phase III Randomized Study. Epidemiology and Vaccinal Prevention 21:6, pages 65-81.
Crossref
Crossref
Lucy A. McNamara, Andrew J. Pollard & Lee H. Harrison. 2023. Plotkin's Vaccines. Plotkin's Vaccines
664
689.e12
.
Kimberly N. Garces, Alexandra N. Cocores, Peter J. Goadsby & Teshamae S. Monteith. (2022) Headache After Vaccination: An Update on Recent Clinical Trials and Real-World Reporting. Current Pain and Headache Reports 26:12, pages 895-918.
Crossref
Crossref
Jessica Huston, Kevin Galicia & Eric F. Egelund. (2021) MenQuadfi (MenACWY-TT): A New Vaccine for Meningococcal Serogroups ACWY. Annals of Pharmacotherapy 56:6, pages 727-735.
Crossref
Crossref
Giada Maria Di Pietro, Giulia Biffi, Massimo Luca Castellazzi, Claudia Tagliabue, Raffaella Pinzani, Samantha Bosis & Paola Giovanna Marchisio. (2022) Meningococcal Disease in Pediatric Age: A Focus on Epidemiology and Prevention. International Journal of Environmental Research and Public Health 19:7, pages 4035.
Crossref
Crossref
Matthew J. Cornish, James A. Hedrick, Alvin A. Gabrielsen, Anthony D. Johnson, L. Miriam Pina, Christine Rehm, Judy Pan, David Neveu, Xavier Da Costa, Emilia Jordanov & Mandeep S. Dhingra. (2022) Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: A Phase II study. Vaccine 40:10, pages 1421-1438.
Crossref
Crossref
Jing Zhao, Gang Hu, Yi Huang, Yingchun Huang, Xin Wei & Jianyou Shi. (2021) Polysaccharide conjugate vaccine: A kind of vaccine with great development potential. Chinese Chemical Letters 32:4, pages 1331-1340.
Crossref
Crossref
M. S. Dhingra, L. Namazova-Baranova, J. L. Arredondo-Garcia, K.-H. Kim, K. Limkittikul, W. Jantarabenjakul, O. Perminova, I. A. R. Kobashi, C.-W. Bae, J. Ojeda, J. Park, D. Chansinghakul, S. B'Chir, D. Neveu, M. Bonaparte & E. Jordanov. (2021) Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine administered concomitantly with other paediatric vaccines in toddlers: a phase III randomised study. Epidemiology and Infection 149.
Crossref
Crossref
D. van der Vliet, T. Vesikari, B. Sandner, F. Martinón-Torres, G. Muzsay, A. Forsten, T. Adelt, C. Diaz Gonzalez, R. Simko, S. B'Chir, D. Neveu, E. Jordanov & M. S. Dhingra. (2021)
Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT)
vs
. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naïve and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study
. Epidemiology and Infection 149.
Crossref
Crossref
Mariagrazia Pizza, Rafik Bekkat-Berkani & Rino Rappuoli. (2020) Vaccines against Meningococcal Diseases. Microorganisms 8:10, pages 1521.
Crossref
Crossref
Sarah A. Mbaeyi, Catherine H. Bozio, Jonathan Duffy, Lorry G. Rubin, Susan Hariri, David S. Stephens & Jessica R. MacNeil. (2020) Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR. Recommendations and Reports 69:9, pages 1-41.
Crossref
Crossref